Biodexa Pharmaceuticals Files Form 6-K
Ticker: BDRX · Form: 6-K · Filed: Feb 10, 2025 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Feb 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, company-update
TL;DR
Biodexa (formerly Midatech) filed a 6-K on Feb 10, 2025, confirming 20-F annual report filings.
AI Summary
Biodexa Pharmaceuticals PLC filed a Form 6-K on February 10, 2025, to report information for the month of February 2025. The company, formerly known as Midatech Pharma Plc, is incorporated in the UK and its principal executive office is located in Cardiff. This filing indicates they will file annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Biodexa Pharmaceuticals PLC's reporting status and corporate information.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- Biodexa Pharmaceuticals PLC (company) — Registrant
- Midatech Pharma Plc (company) — Former company name
- February 2025 (date) — Reporting period
- February 10, 2025 (date) — Filing date
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report form
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information for the month of February 2025 and to indicate that Biodexa Pharmaceuticals PLC files annual reports under Form 20-F.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on February 10, 2025.
What was Biodexa Pharmaceuticals PLC's former company name?
Biodexa Pharmaceuticals PLC's former company name was Midatech Pharma Plc.
Where is Biodexa Pharmaceuticals PLC's principal executive office located?
Biodexa Pharmaceuticals PLC's principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Does this filing contain new financial information or operational updates?
No, this filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 and does not appear to contain new financial or operational information beyond administrative reporting.
Filing Stats: 245 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2025-02-10 08:30:26
Filing Documents
- f6k_021025.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-25-000710.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: February 10, 2025 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer